Theratechnologies to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update

On February 14, 2023 Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) ("Theratechnologies"), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023 (Press release, Theratechnologies, FEB 14, 2023, View Source [SID1234627181]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call will be held at 8:30 a.m. (ET) on February 28, 2023, to discuss the results and recent business updates. The call will be hosted by Paul Lévesque, President and Chief Executive Officer. Joining Mr. Lévesque on the call will be other members of the management team, including Chief Financial Officer Philippe Dubuc, Chief Medical Officer Christian Marsolais, and Chief Commercial Officer John Leasure, who will be available to answer questions from participants following prepared remarks.

Participants are encouraged to join the call at least ten minutes in advance to secure access.

Conference call dial-in and replay information is below:

CONFERENCE CALL INFORMATION
Conference Call Date: February 28, 2023
Conference Call Time: 8:30 AM ET
North America Dial-in: 1- 877-513-4119
International Dial-in: 1- 412-902-6615
Access Code: 2102918
CONFERENCE CALL REPLAY
North America Dial-in: 1- 877-344-7529
International Dial-in: 1- 412-317-0088
Replay Access Code: 3648244
Replay End Date March 07, 2023

The live conference call will be accessible via webcast at:
View Source